Alkermes Ends Generic VIVITROL Supply Agreement with Amneal
I'm LongbridgeAI, I can summarize articles.Alkermes terminated its Authorized Generic Product Supply Agreement with Amneal Pharmaceuticals for a generic version of VIVITROL on July 6, 2026. The termination followed Alkermes' notification that Amneal failed to meet contractual terms, and Amneal's subsequent refusal to order batches. No penalties or further obligations remain between the parties. Additionally, analyst ratings on ALKS stock vary, with some suggesting a Buy at $65.00, while TipRanks’ AI Analyst rates it as Neutral.
Alkermes ( (ALKS) ) has provided an announcement.
On July 6, 2026, Alkermes and Amneal Pharmaceuticals terminated their Authorized Generic Product Supply Agreement covering a generic version of VIVITROL, originally signed on September 9, 2025. The deal had allowed Amneal to distribute a limited quantity of an authorized generic VIVITROL in the United States for one year following a third‑party product launch, with Alkermes’ Irish subsidiary supplying product at a premium to manufacturing cost and sharing in net profits.
After Alkermes notified Amneal that it had not met certain contractual terms, Amneal responded within the cure period that it did not wish to order any batches under the agreement, leading to the early termination. Alkermes incurred no penalties, no further payments or obligations remain between the parties, and both companies agreed to release all related claims, limiting operational and financial impact from the discontinued arrangement.
The most recent analyst rating on (ALKS) stock is a Buy
with a $65.00 price target.
To see the full list of analyst forecasts on Alkermes stock,
see the ALKS Stock Forecast page.
Spark’s Take on ALKS Stock
According to Spark, TipRanks’ AI Analyst, ALKS is a Neutral.
ALKS scores as a mid-range opportunity: strong margins, a return to profitability, positive cash generation, and constructive price trend support the score. The largest constraints are the sharp step-up in leverage, weakening free-cash-flow momentum, and a high P/E that leaves less room for operational setbacks despite an upbeat commercial/pipeline update.
To see Spark’s full report on ALKS stock,
click here.
More about Alkermes
Alkermes plc is a biopharmaceutical company whose portfolio includes VIVITROL, an extended‑release injectable formulation of naltrexone used in the treatment of opioid and alcohol dependence. Through its subsidiary Alkermes Pharma Ireland Limited, the company manufactures and supplies products for distribution in the U.S. market, often via partnership and licensing arrangements with other pharmaceutical firms.
Average Trading Volume: 2,255,444
Technical Sentiment Signal: Buy
Current Market Cap: $9.19B
For an in-depth examination of ALKS stock, go to TipRanks’ Overview page.